期刊文献+

基因多态性与非酒精性脂肪性肝病相关性研究

Meta-Analysis of PNPLA3 Gene Polymorphism and Non-Alcoholic Fatty Liver Disease
原文传递
导出
摘要 目的探讨PNPL43rs738409基因多态性与非酒精性脂肪性肝病(non—alcoholicfattyliverdiseas@,NAFLD)发生的关系。方法利用计算机在万方数据库、中国全文期刊数据库和维普数据库、Embase和Pubmed数据库中检索PNPLA3rs738409基因多态性与NAFLD发生的相关文献,并应用RevMan5.0软件对符合人选标准的文献进行异质性检验和效应值合并,同时进行敏感性分析和偏倚评估。结果纳入符合条件的相关文献11篇,共计NAFLD组1069例,对照组2127例。根据异质性检验结果,采用相应的效应模型进行合并分析。结果PNPLA3rs738409位点GC、CC、GC+CC基因型与NAFLD的合并OR值(95%a)分别为0.63(0.36—1.12)、0.22(0.11~0.43)、0.50(0.15~1.66),Z=1.57、4.43、1.13,P〉0.05、〈0.05、〉0.05。各研究的敏感性分析较稳定且无发表偏倚。结论PNPLA3rs738409CC基因型与NAFLD的发生密切相关。 Objective To explore the relationship between patatin -like phospholipase domain containing3 (PNPLA3) rs738409 gene polymorphism and non - alcoholic fatty liver disease (NAFLD). Methods The literature concerning PNPLA3 rs738409 gene polymorphism and non - alcoholic fatty liver disease was comprehensively retrieved in WanFang DATA , Chinese full - text journal databases, VIP database, Embase and Pubmcd database. The included literature was tested for heterogeneity, merging effect value, sensitivity analysis and bias evaluation with RevMan 5. 0 software. There were 11 pieces of literature included, which covered 1069 cases of NAFLD and 2127 cases of controls. The corresponding effect model was used for pooled analysis according to heterogeneity test results. Results For NAFLD, the pooled OR and 95% CI of gene type GC,CC,GC + CC were 0.63(0.36 -1.12) (Z=1. 57, P 〉0.05), 0.22(0.11 -0.43) (Z=4. 43, P 〈0.05), and 0.50(0.15 - 1.66) (Z = 1.13, P 〉0.05) respectively. The sensitiveness analysis was stable and there was no publication bias. Conclusions PNPLA3 rs738409 CC gene type is closely related to the occurrence of NAFLD.
出处 《社区医学杂志》 2013年第20期8-10,共3页 Journal Of Community Medicine
关键词 PNPLA3基因 非酒精性脂肪性肝病 基因多态性 META分析 肝硬化 PNPLA3 gene gene polymorphism non - alcoholic fatty liver disease meta - analysis
  • 相关文献

参考文献3

二级参考文献42

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649. 被引量:1
  • 3Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219. 被引量:1
  • 4Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231. 被引量:1
  • 5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397. 被引量:1
  • 6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490. 被引量:1
  • 7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44. 被引量:1
  • 8Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261. 被引量:1
  • 9Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215. 被引量:1
  • 10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861. 被引量:1

共引文献1511

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部